摘要
目的探讨齐拉西酮与利培酮对女性精神分裂症患者的疗效及安全性。方法 80例女性精神分裂症患者随机分为齐拉西酮组与利培酮组,每组40例。分别给予齐拉西酮和利培酮治疗,疗程8周。以阳性和阴性症状量表(PANSS)评定疗效、治疗中出现的症状量表(TESS)评定不良反应。结果齐拉西酮组显效率为84.21%,有效率为94.74%;利培酮组显效率为78.38%,有效率为91.89%,两组比较差异无统计学意义(P>0.05)。两组患者的PANSS评分治疗后均较治疗前明显下降,差异有统计学意义(P<0.01)。齐拉西酮组体重增加和内分泌改变等不良反应发生率显著低于利培酮组,差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮对女性精神分裂症的疗效相当,齐拉西酮对体重的影响和内分泌改变显著少于利培酮,是治疗女性精神分裂症患者的理想药物。
Objective To explore the curative effect and safety of ziprasidone and risperidone in the treatment of female schizophrenia. Methods A total of 80 female schizophrenia patients were randomly divided into ziprasidone group and risperidone group, with 40 cases in each group. The retrospective therapies by ziprasidone and risperidone were given to the two groups for 8 weeks. Positive and negative syndrome scale for schizophrenia （PANSS） was applied for curative effect assessment, and treatment emergent symptom scale （TESS） was used to assess the adverse reactions. Results In the ziprasidone group, the excellent effect rate was 84.21%, and the effective rate was 94.74%. These two rates in the risperidone group were 78.38%and 91.89%. There was no statistically significant difference between the two groups （P〉0.05）. The PANSS scores of the two groups decreased significantly after treatment, compared with those before treatment. The difference had statistical significance （P〈0.01）. The incidences of adverse reactions, such as increased weight and changed endocrine, in the ziprasidone group were obviously lower than those in the risperidone group. The difference had statistical significance （P〈0.05）. Conclusion Ziprasidone and risperidone have similar curative effects in the treatment of female schizophrenia, while ziprasidone has much less influences on weight and endocrine than risperidone. Therefore, ziprasidone is an ideal drug for treating female schizophrenia.
出处
《中国实用医药》
2014年第31期24-25,共2页
China Practical Medicine
